Despite setbacks and funding cuts — and a quieting of the hype blaring its arrival — multiple CRISPR-based trials are ...

CRISPR Therapeutics recently presented new preclinical data at the ESGCT 2025 Annual Congress showing its investigational CTX460, using the SyNTase gene editing platform, achieved greater than 90% ...

CRISPR Therapeutics’ stock is surging as in-vivo therapies show promise. Learn about CRSP stock's risks, long-term upside, ...

BRENTFORD, ENGLAND, UNITED KINGDOM, October 14, 2025 / EINPresswire.com / -- The global CRISPR gene-editing market is expected to witness significant growth, projected to rise from a valuation of US$ ...

A CRISPR-Cas9-based therapy targeting the gene encoding transthyretin greatly reduced transthyretin levels in patients with ...

Baby KJ's medical team intend to ask the FDA to start a clinical trial that would be open to patients with seven different ...

In early October 2025, Intellia Therapeutics presented new clinical results at the European Society of Gene & Cell Therapy Congress, highlighting long-term safety and efficacy data for its ...

As a result, the technology stands at a complicated intersection in the fight against a shifting climate. Breeding plants to ...

In May, a historic moment in science and medicine was captured in a single photo that circulated across news outlets ...

CRISPR is a gene-editing tool that acts like “molecular scissors,” but using it on cancer is complex. The technology’s biggest impact so far is in research labs, helping scientists understand how ...

Preclinical data presented at the European Society of Gene and Cell Therapy (ESGCT) highlight a potential best-in-class profile--The AATD ...

That’s why a team from UC San Diego in La Jolla set out with Yale University researchers to develop a new system for gene ...